Phathom Pharmaceuticals Inc (PHAT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
4.41 +0.19 (+4.50%) 03/14/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 4.45 +0.04 (+0.91%) 18:25 ET
for Fri, Mar 14th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Sales | 55,252 | 682 | 0 | 0 | 0 |
Cost of Goods | 7,973 | 167 | N/A | N/A | N/A |
Gross Profit | 47,279 | 515 | N/A | N/A | N/A |
Operating Expenses | 325,719 | 167,994 | 172,440 | 135,080 | 125,665 |
Operating Income | -277,467 | -167,312 | -172,440 | -135,080 | -125,665 |
Interest Expense | 72,009 | 41,968 | 27,305 | 6,788 | 4,581 |
Other Income | 15,150 | 7,688 | 2,022 | -2,015 | 1,178 |
Pre-tax Income | -334,326 | -201,592 | -197,723 | -143,883 | -129,068 |
Net Income Continuous | -334,326 | -201,592 | -197,723 | -143,883 | -129,068 |
Net Income | $-334,326 | $-201,592 | $-197,723 | $-143,883 | $-129,068 |
EPS Basic Total Ops | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 |
EPS Basic Continuous Ops | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 |
EPS Diluted Total Ops | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 |
EPS Diluted Continuous Ops | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 |
EPS Diluted Before Non-Recurring Items | N/A | -2.53 | -5.05 | -3.89 | -3.88 |
EBITDA(a) | $-274,480 | $-164,860 | $-169,710 | $-130,964 | $-124,069 |